# PRODUCT INFORMATION



# Atorvastatin-d<sub>5</sub> (calcium salt)

Item No. 25043

CAS Registry No.: 222412-82-0

Formal Name: 2-(4-fluorophenyl)-βR,δR-dihydroxy-

> 5-(1-methylethyl)-3-(phenyl-d<sub>5</sub>)-4-[(phenylamino)carbonyl]-1H-pyrrole-1heptanoic acid, hemicalcium salt

 $C_{33}H_{29}D_5FN_2O_5 \bullet 1/2Ca$  562.7 MF:

FW:


**Chemical Purity:** ≥98% Atorvastatin

Deuterium

Incorporation:  $\geq$ 99% deuterated forms (d<sub>1</sub>-d<sub>5</sub>);  $\leq$ 1% d<sub>0</sub>

Supplied as: A solid -20°C Storage: Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



## **Laboratory Procedures**

Atorvastatin-d<sub>5</sub> (calcium salt) is intended for use as an internal standard for the quantification of atorvastatin (Item No. 10493) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Atorvastatin-d<sub>5</sub> (calcium salt) is supplied as a solid. A stock solution may be made by dissolving the atorvastatin-d<sub>5</sub> (calcium salt) in the solvent of choice. Atorvastatin-d<sub>5</sub> (calcium salt) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of atorvastatin-d<sub>5</sub> (calcium salt) in these solvents is approximately 0.5, 15, and 25 mg/ml, respectively.

## Description

Atorvastatin is an inhibitor of HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol synthesis, that has IC50 values of 73, 102, and 0.6 nM for HepG2 cells, human fibroblasts, and rat hepatocytes, respectively. Formulations containing atorvastatin have been used in the treatment of hypercholesterolemia and certain dyslipidemias.

#### Reference

1. Shaw, M.K., Newton, R.S., Sliskovic, D.R., et al. Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase. Biochem. Biophys. Res. Commun. 170(2), 726-734 (1990).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

# WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 02/19/2024

### **CAYMAN CHEMICAL**

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM